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A paraplegic patient with fever and 
leucocytosis: not always what it seems
ABSTRACT
A 54-year-old obese woman with a history of spina bifida was admitted to the hospital with malaise and fever ac-
companied by leucocytosis, thrombocytosis, and hypercalcaemia. As treatment for neurogenic bladder dysfunction 
she had a suprapubic catheter. Diagnostic workup for osteomyelitis revealed an unknown mass originating from 
the urinary bladder on MRI of the pelvis. Further diagnostic analyses showed that the mass was a squamous-cell 
carcinoma (SCC) with laboratory abnormalities as paraneoplastic phenomena mediated by PTH-related peptide 
and cytokines released by the SCC. Despite radiotherapy the patient died within two months after initial diagnosis. 
Squamous-cell carcinoma of the bladder is rare in western countries. In unresectable or metastatic disease survival 
rates are low due to low responsiveness to standard chemotherapy. Concurrent chemoradiotherapy might be an 
alternative in unresectable or locally advanced disease; however, evidence to support this is lacking. The poor 
survival in these patients raises the question of whether high-risk groups for SCC of the bladder, like paraplegic 
patients or patient with neurogenic bladder dysfunction, should receive screening even though the ideal starting 
point and frequency are still unknown.
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Introduction
Patients with neurogenic bladder dysfunction can 
be treated with a suprapubic catheter. Here we present 
a case of a patient with a squamous cell carcinoma (SCC) 
of the bladder around the suprapubic catheter tract and 
consequentially three paraneoplastic phenomena, mim-
icking infection. Written, informed consent was obtained 
from a legally authorised representative for anonymised 
patient information to be published in this article.
Case report
A 54-year-old obese (BMI = 48.9 kg/m2) woman was 
admitted to the hospital with malaise and fever. She was 
known with a history of smoking, type 2 diabetes mellitus, 
and spina bifida. The latter was accompanied by paresis of 
both legs and neurogenic bladder dysfunction for which 
she had had a suprapubic catheter for the last 30 years 
ago with follow-up by her general practitioner. Physical 
examination at admission was normal except for two ul-
cers: one stage IV pressure ulcer at the tailbone and one 
ulcer at the entrance of the suprapubic cystostomy tract. 
Laboratory findings revealed a thrombocytosis, neutro-
philic leukocytosis, and increased CRP (Tab. 1). Both 
urine analysis and chest radiography were unremarkable. 
An MRI-scan of the pelvis was made to rule out 
ischial tuberosity osteomyelitis beneath the stage IV 
pressure ulcer. The MRI showed no signs of osteomy-
elitis, but an unknown mass originating from the urinary 
bladder around the suprapubic catheter extending to the 
entrance of the suprapubic cystostomy (Fig. 1). A biopsy 
revealed a moderately differentiated invasive squamous 
cell carcinoma (SCC). CT-scan of the chest, abdomen, 
and pelvis showed no distant metastases. 
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Table 1. Laboratory test results at admission and after two weeks
Reference Hospital admission After two weeks
Haemoglobin [mmol/L] 7.5–10.0 5.5 5.1
Haematocrit [L/L] 0.35–0.45 0.28 0.26
Thrombocytes [/nL] 150–400 510 600
Leukocytes [/nL] 4.0–10.0 43.5 54.9
Neutrophilic leukocytes [/nL] 1.5–7.5 40 –
Lactate dehydrogenase [U/L] 122–222 254 –
Alkalic phosphatase [IU/L] 33.0–98.0 181 –
Creatinine [µmol/L)] 50–100 54 65
Urea [mmol/L] 2.5–6.4 3.6 3.4
Creatinine clearance [MDRD, ml/min] > 60 > 60
Natrium [mmol/L] 135–145 136 137
Potassium [mmol/L] 3.5–5.0 3.4 3.5
Calcium, corrected [mmol/L] 2.10–2.55 2.55 3.43
Albumin [g/L] 35–50 31 28
Magnesium [mmol/L] 0.75–1.0 0.61 0.6
PTH-related protein [pmol/L] < 0.6 – 2
PTH [pmol/L] 1.6–6.9 0.94 –
25-OH vit D [nmol/L] > 50 34 26
1,25 di-OH vitamine D [pmol/L] 47–130 – 45
Monoclonal immunoglobulins [g/L] Positive, IgG lambda: < 2 Urine: negative
TSH [mIU/L] 0.27–4.2 1.6 –
Vitamin A [µmol/L] 0.7–2.1 1.1 –
Thrombopoietin [IE/ml] 4–32 130 –
Initially, intravenous antibiotic treatment with cipro-
floxacin and flucloxacillin was started to treat a potential 
underlying infection. Treatment was stopped after two 
weeks due to lack of clinical benefit, multiple negative 
blood cultures, and persistent leucocytosis and fever. In 
addition, a progressive hypercalcaemia of 3.43 mmol/L 
was found, which was unlikely to be explained by com-
mon causes like immobilisation, osteolytic metastases, 
or dehydration because the patient had already been im-
mobilised for many years, osteolytic metastases were ab-
sent, and hydration did not improve calcium levels. The 
concomitant suppressed parathyroid hormone (PTH) 
of 0.94 pmol/L was probably a normal physiological 
reaction and suggested another mediator responsible 
for the hypercalcaemia. Closer investigation showed an 
elevated PTH-related protein of 2.0 pmol/L. Likewise, 
an elevated thrombopoietin of 130 IE/ml was found as 
a mediator for the thrombocytosis (Tab. 1). 
The final diagnosis was a squamous cell carcinoma of 
the bladder (cT4N1M0) accompanied by a paraneoplas-
tic syndrome of fever, leukocytosis, thrombocytosis, and 
hypercalcaemia. The patient was ineligible for radical 
cystectomy and concurrent chemoradiation based on 
a WHO performance status of 2. Therefore, treatment 
was started with bisphosphonates and radiotherapy 
(51 Gy in 17 fractions). This treatment normalised 
calcium levels and stopped the fever. After six weeks 
Figure 1. MRI showing a squamous-cell carcinoma (large 
dashed line) around the suprapubic catheter (small dotted line)
73
Ashley J.R. De Bie et al., A paraplegic patient with fever and leucocytosis
of hospitalisation the patient was discharged to strengthen 
at home. Unfortunately, one week after discharge she was 
readmitted due to a deteriorating condition. A CT-scan of 
the chest and abdomen showed new pulmonary metastases, 
and in consultation with the patient supportive care was 
started. The patient died within two weeks in a hospice. 
Discussion 
Squamous cell carcinoma (SCC) of the bladder 
consists of two subtypes: the bilharzial-associated SCC 
(B-SCC) and non-bilharzial-associated SCC (NB-SCC). 
The B-SCC is mainly found in regions where schistoso-
miasis is endemic, representing 30–50% of bladder cases 
in these areas [1, 2]. In western countries the NB-SCC 
subtype is more common, which accounts for 2–5% of 
bladder neoplasms [1–3]. Important risk factors for 
NB-SCC are smoking, recurrent urinary infections, and 
the use of chronic indwelling urinary catheters causing re-
active chronic inflammatory and proliferative pathologic 
changes of the bladder [1, 4, 5]. The incidence of NB-SCC 
in paraplegic patients is therefore 16–28 times higher.
Paraneoplastic syndromes are well known in pulmo-
nary SCC. These syndromes have also occasionally been re-
ported in SCC of the bladder [6–9]. In this case, the patient 
presented with a progressive hypercalcaemia and elevated 
PTH-related peptide (PTH-rP), also known as “humorally 
mediated hypercalcaemia of malignancy”. This is caused 
by cancer cells producing PTH-rP with an almost identical 
structure to PTH, which is therefore able to bind bone and 
renal PTH-1 receptors. This enhances renal reabsorption 
and osseous release of calcium [10, 11]. Besides the hy-
percalcaemia, PTH-rP might also be responsible for the 
leukocytosis and thrombocytosis. PTH-rP is able to stimu-
late interleukin-6 (IL-6) secretion from osteoblasts, aside 
from possible IL-6 secretion by the malignancy itself, which 
has been described in SCC. IL-6 enhances production of 
haematopoietic growth factors like granulocyte-colony 
stimulating factor (G-CSF) and thrombopoietin, resulting 
in leukocytosis and thrombocytosis [11]. 
Although we did not measure G-CSF or cytokines, 
the elevated levels of thrombopoietin and PTH-rP com-
bined with the excessively high neutrophilic leukocytes in 
the absence of positive blood cultures or steroids suggest 
that all three phenomena were neoplastic. 
Substantial evidence for standard guidelines to 
treat NB-SCC are lacking since the incidence is low. 
The main treatment for non-metastatic NB-SCC is 
radical cystectomy. Preoperative radiotherapy might 
reduce local recurrence and improve survival [3, 4]. 
However, despite radical cystectomy and radiotherapy, 
the prognosis of non-metastatic NB-SCC remains poor 
with a five-year survival of 34–50%, which is mainly 
related to failure of locoregional control [1, 3, 4]. Even 
though distant metastases are infrequent (8–10%), the 
presence of metastases or unresectable malignancy re-
duces the survival dramatically. The reasons for this poor 
outcome is that NB-SCC shows only low responsiveness 
for chemotherapy commonly used in urothelial cancer. 
One study demonstrated some response to treatment 
with ifosfamide, paclitaxel, and cisplatin with a median 
survival of 8.9 months, although conclusions are hampered 
by the small sample size [3, 12]. An alternative treatment 
for unresectable or locally advanced disease might be 
concurrent chemoradiotherapy. However, evidence to 
support this is scarce. Recently, immunotherapy target-
ing the PD-1 pathway showed promising results. Both 
atezolizumab in patients previously treated with platinum 
based therapy and pembrolizumab in patients ineligible 
for platinum-based regimes have demonstrated an effect 
in metastatic urothelial cancer [13, 14]. The use of immu-
notherapy in metastatic squamous cell carcinoma is still 
unknown and is currently being investigated in a clinical 
trial using durvalumab and tremelimumab (Clinicaltrial.
gov: NCT03430895).
To prevent NB-SCC it is important to reduce the 
use of chronic indwelling urinary catheters in long-term 
paraplegic patients. In addition, early discovery with 
surveillance cystoscopy and urine cytology might be 
considered in high-risk groups with neurogenic bladder 
dysfunction, like spina bifida. However, screening on 
NB-SCC is still under debate because the ideal starting 
point and frequency are unknown [1, 5, 15, 16]. 
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